LV ejection fraction was 44%. The ICD was routinely checked after the implant, and the patient received remote monitoring (RM) system. 3 Five years later, AHRE was detected by RM, and the patient was called for an outpatient visit ( Figure 2 ). Atrial fibrillation episode was discovered lasting for more than 24 h and the patient was complaining for occurrence of dyspnoea and chest pain but he was not feeling palpitation or rhythm irregularity. An echocardiogram was repeated and LV ejection fraction felt down to 30% and mild left atrial dilatation was found. The patient was hospitalized for initial HF symptoms and suspect angina. A coronary angiography showed patency of the bypass graft and no critical stenosis on native coronary arteries. The first therapeutic action was to start antithrombotic therapy with rivaroxaban. 1 The thrombo-embolic risk of the patient was classified as high with a CHA 2 DS 2 VASc score of 4. The second action was to choose between rhythm or rate control strategy. Initially a rate control approach was followed, starting treatment with beta-blocker (bisoprolol 10 mg/day). However, after 3 months, patient was still complaining of symptoms, mainly fatigue, dyspnoea, and chest pain during stress. Since the lack of improvement in symptoms, we decided to switch to a rhythm control strategy. 1 Amiodarone therapy was started, and an internal electrical cardioversion from the device was performed restoring sinus rhythm ( Figure 3 ). At 1-month follow-up after electrical cardioversion, the patient was feeling better, no more chest pain, fatigue, or dyspnoea were reported. An echocardiogram performed after 60 days showed an improved LV function with an ejection fraction of 38%. After 3 years of follow-up, AF burden was still 0% and no more AHREs episodes were detected from the ICD, and the patient was in New York Heart Association (NYHA) functional Class I (Figure 4) .
Discussion
Atrial fibrillation and HF frequently coexist in the same patient, often negatively promoting the course of each other. Dyspnoea or chest pain without more specific arrhythmic symptoms may delay the diagnosis of AF in HF patients. Given the poor outcomes in patients with HF who developed AF, a prompt diagnosis and therapy could be of paramount importance in these patients.
Cardiac implantable electronic devices (CIEDs) with an atrial lead or dipole for sensing allow continuous monitoring of atrial rhythm potentially highlighting AHRE that enable early detection of AF. Prior studies have demonstrated that the detection of AHRE correlates with electrocardiographic documentation of AF. 4, 5 Atrial fibrillation can affect HF triggering inappropriate shocks, precipitating HF, and increasing the risk of thrombo-embolic stroke. The principal benefits of RM are early arrhythmia detection associated with a prompt clinical management and patient continuous monitoring allowing patient-tailored strategy of treatment. 6, 7 The Home Guide Registry demonstrated that automatic RM allows early detection of AF with high sensitivity and appropriate reaction to optimize medical treatment. 8 Useful and detailed information about AF episodes such as arrhythmia recurrences and burden, number and duration of the episodes, mean and maximum ventricular rate are stored differently in CIEDs according to the manufacturer. If the reliability of RM for AF early detection, notification and quantification is well established, 9-11 evidences regarding the use of this technology for early anticoagulation are less clear. [12] [13] [14] [15] Ongoing clinical trials will probably better clarify the benefit of oral anticoagulation in patients with AHRE [Apixaban for the Reduction of ThromboEmbolism in Patients With Device-Detected Sub-clinical Atrial Fibrillation (ARTESIA) and Non-vitamin K antagonist Oral anticoagulations in patients with Atrial High-rate episodes (NOAH-AFNET)].
In our patient, rhythm control strategy showed better results compared to rate control strategy to control symptoms, in particular chest pain during stress.
Guidelines suggest that HF patients with AF and severe symptoms may benefit from rhythm control therapy in addition to rate control.
1 Several studies and meta-analysis tried to compare rhythm vs. rate control strategy in patients with HF. [16] [17] [18] [19] Although no significant reduction of mortality rate, hospitalization, or thromboembolism was found with rhythm control strategy, persistence of sinus rhythm improves LV function, exercise capacity, and quality of life. 18, 20, 21 Once the rhythm control strategy was chosen for our patient, the use of a new oral anticoagulant allowed a quicker elective cardioversion compared to vitamin K antagonist (VKA).
In patients undergoing electrical cardioversion, longterm novel oral anticoagulant (NOAC) therapy showed similar results on thrombo-embolic risk prevention compared to warfarin. [22] [23] [24] Moreover, the predictable pharmacokinetics and pharmacodynamics of NOACs allows a more rapid and reliable time to cardioversion without any delay to achieve stable therapeutic international normalized ratio (INR) values as it often the case with VKA strategy. 22 In conclusion, RM by CIEDs allows early detection of arrhythmia episodes in HF patients even in the absence of clear symptoms. Continuous monitoring enables physician to tailor arrhythmia management and treatment in these patients.
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